Nanni Schmitt

7PUBLICATIONS
19CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 30, 2026
Dose-Adjusted Treatment With 7-Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia.

|Dec 23, 2025
Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data.

Jonathan Bobak, Philipp Spohr, Sarah Richter

|Oct 13, 2025
Primary CD34+ cells of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome are highly sensitive to targeted treatment with TAK-243.

Daniel Nowak, Marie Demmerle, Alessa Klär

|Aug 21, 2025
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.

Nanni Schmitt, Jana-Julia Siegler, Alexandra Beck

|Mar 18, 2023
Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.

Qingyu Xu, Alexander Streuer, Johann-Christoph Jann

|Jan 21, 2023
In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies.

Qingyu Xu, Eva Altrock, Nanni Schmitt

Pageof 2

Frequent Collaborators

4 joint publications

Alexander Streuer

3 joint publications

Daniel Nowak

2 joint publications

Ali Darwich

2 joint publications

Vladimir Riabov